Second Opinion · 2026-07-19 · 5 min
Key moments - from our scoring
Substance score
34 / 100
Five dimensions, 20 points each
Dr. Michael Wilkes addresses a growing consumer trend: blood tests for Alzheimer's disease marketed directly to healthy people concerned about cognitive decline. While these tests measure amyloid and tau proteins linked to Alzheimer's pathology, Wilkes emphasizes a critical distinction - detecting amyloid in a cognitively normal person is not predictive of disease development. Research shows only 18% of healthy adults with positive test results develop dementia within 10 years, meaning 82% of positive results produce no disease progression. This gap between detection and prediction matters enormously because positive results often drive patients toward anti-amyloid drugs like aducanumab and lecanemab, which carry serious risks including brain swelling, microhemorrhages, seizures, and prolonged hospitalization, while their clinical benefits remain debated. Investigative journalist Jeanne Lenzer's reporting on patient complications, combined with Wilkes' concerns about financial conflicts of interest involving the Alzheimer's Association and test manufacturers, privacy risks from third-party testing companies, and potential insurance implications, creates a compelling case for caution. The episode urges patients like his case study Annie - a 62-year-old with family history - to ask their primary care physician or neurologist one key question before testing: "How will knowing this result change my care?"
Studies show that among cognitively normal adults with a positive test, only 18% develop dementia within 10 years, meaning 82% of positive results do not lead to Alzheimer's dementia in that timeframe.
Anti-amyloid drugs can cause brain swelling, microhemorrhages, seizures, and prolonged hospitalizations, according to investigative reporting on patient outcomes after receiving these medications.
Yes, a positive test result could affect eligibility for long-term care insurance and may be disclosed to health insurers or employers if obtained through private testing companies that lack healthcare privacy protections.
Dr. Wilkes recommends consulting with your primary care physician or a neurologist specializing in memory disorders before pursuing testing for amyloid or other Alzheimer's biomarkers.
While these drugs do remove amyloid protein from the brain, researchers still debate whether they actually improve memory or daily functioning for patients.
Our reviewer’s read on each dimension, with quotes from the episode.
For a 5-minute health monologue there are a few non-obvious points (amyloid detection ≠ dementia prediction, insurance/privacy risks), but it's a single-topic consumer segment with essentially no B2B operator value and limited idea density.
Detecting amyloid is not the same as predicting who will develop Alzheimer's disease
How will knowing this result change my care?
The 'overdiagnosis / earlier detection isn't always better' angle is a reasonably thoughtful contrarian take within medicine, but it's a familiar skepticism trope rather than genuinely fresh first-principles thinking.
Medicine has learned again and again that earlier detection only helps when it leads to treatment that clearly improves lives
a positive result raises far more questions than it answers
There is no guest at all - this is a solo commentary by a physician host; the only external voice cited is a journalist referenced secondhand, offering no interview substance.
This is Dr. Michael Wilkes with a second opinion
Investigative journalist Jeanne Lenzer writes in the news outlet the Lever
Contains a few concrete data points and named sources (18% figure, named journalist and outlet, specific complications), but overall remains fairly general with no company names, dollar figures, or granular study detail.
only 18% develop dementia within 10 years
Brain swelling, bleeding, seizures and prolonged hospitalizations
This is a scripted monologue with no host-guest exchange, no questions, follow-ups, or pushback - there is no conversation to evaluate.
This is Dr. Michael Wilkes with a second opinion, a patient I will call. Annie is 62.
Computed from the transcript - who did the talking, and the words that came up most.
New Alzheimer's blood tests are accurate, available, and increasingly advertised - but for healthy people, a positive result is rarely useful.
Transcribed and scored by The B2B Podcast Index.
Speaker A: This is Dr. Michael Wilkes with a second opinion, a patient I will call. Annie is 62. For many years, she has worried she might develop Alzheimer's disease. Her mother began having memory problems in her early 70s, but she died of cancer before anybody could determine whether she had Alzheimer's. But now Annie wants answers, but also worries what those answers might mean. Recently, she saw an ad for a blood test for Alzheimer's offered online by a private company. She asked me if she should take it. That question is becoming increasingly common as these tests become more widely available and are being heavily promoted. The test measures proteins linked to amyloid, a substance that accumulates in the brains of people with Alzheimer's. For patients already struggling with memory loss, the test can help confirm the diagnosis. But using the test to screen healthy people like Annie is far more problematic. That's because an important distinction gets lost. Detecting amyloid is not the same as predicting who will develop Alzheimer's disease. Studies find that among cognitively normal adults with a positive test, only 18% develop dementia within 10 years, meaning 80 of positive results did not lead to Alzheimer's dementia in that time. For a healthy person, a positive result raises far more questions than it answers. The anxiety around a positive test can push people toward risky treatment in an attempt to prevent progression of a disease that actually may never occur. Investigative journalist Jeanne Lenzer writes in the news outlet the Lever about patients who received new anti amyloid drugs. After receiving positive tests, they went on to develop serious complications. Brain swelling, bleeding, seizures and prolonged hospitalizations. While these drugs do remove amyloid, researchers still debate whether they improve memory or daily functioning. Lenzer raises other issues Annie might also consider. A positive test could affect eligibility for long term care insurance. Also, testing companies may not be bound by the same privacy protections as health care systems. So a test result could end up in the hands of a health insurer or an employer or even online. There are also important conflicts of interest. Some large organizations, like the Alzheimer's association and experts promoting widespread testing have financial ties to the companies that make the tests or the drugs used to treat positive results. That in and of itself is reason to weigh the underlying science very carefully and seek guidance from independent experts. For someone like Annie, the best first step may be talking with her primary care physician or a neurologist who specializes in memory disorders. Medicine has learned again and again that earlier detection only helps when it leads to treatment that clearly improves lives. Before testing, ask a simple question. How will knowing this result change my care? If you can't answer that clearly waiting for better evidence is the wiser choice. This is Dr. Michael Wilks with a second opinion.
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
